Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study

Wang T. et al, (2021), BMC Infectious Diseases, 21

Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure.

Smith DA. et al, (2021), Nature communications, 12

Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT

Cooke GS. et al, (2021), Efficacy and Mechanism Evaluation, 8, 1 - 90

Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019.

Wang T. et al, (2021), Hepatol Commun, 5, 1586 - 1604

Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C

Cooke G. et al, (2021)

Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy

Smith DA. et al, (2021), Journal of Viral Hepatitis

Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID‐19 patients as prognostic markers

Wang T. et al, (2021), Hepatology Communications

Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C

Cooke GS. et al, (2021), Wellcome Open Research, 6, 93 - 93

Efficacy and safety of tenofovir disoproxil fumarate (TDF) in hepatitis B virus (HBV) monoinfection: longitudinal analysis of a UK cohort

Wang T. et al, (2020)

National Institute for Health Research Health Informatics Collaborative: development of a pipeline to collate electronic clinical data for viral hepatitis research.

Smith DA. et al, (2020), BMJ health & care informatics, 27

Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAAs

Smith DA. et al, (2020)

Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia

Nguyen D. et al, (2020), Journal of Hepatology, 73, 794 - 799

Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort

Maponga TG. et al, (2020), Journal of Infection, 81, 121 - 130

Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

Smith DA. et al, (2020)

National Institute for Health Research Health Informatics Collaborative (NIHR HIC): Development of a Pipeline to Collate Electronic Clinical Data for Viral Hepatitis Research

Smith DA. et al, (2019)

Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir

Wing PAC. et al, (2019), Gastroenterology, 157, 692 - 704.e9

Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection

Downs LO. et al, (2019), mBio, 10

Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors

Smith D. et al, (2019), Hepatology, 69, 1861 - 1872

Interpreting Viral Deep Sequencing Data with GLUE

Singer J. et al, (2019), Viruses, 11, 323 - 323

Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

Bonsall D. et al, (2018), Infection and Drug Resistance, Volume 11, 1119 - 1135

Load More

Include forthcoming?